[<sup>177</sup>Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study
Advanced Accelerator Applications
Simron Singh; Daniel Halperin; Sten Myrehaug; Ken Herrmann; Marianne Pavel; Pamela L Kunz; Beth Chasen; Salvatore Tafuto; Secondo Lastoria; Jaume Capdevila; Amparo García-Burillo; Do-Youn Oh; Changhoon Yoo; Thorvardur R Halfdanarson; Stephen Falk; Ilya Folitar; Yufen Zhang; Paola Aimone; Wouter W de Herder; Diego Ferone; all the NETTER-2 Trial Investigators